The NHS will deny 90 per cent of eligible obese patients the “King Kong” of weight loss jabs, citing budget pressures. The ...
Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health ...
US: Sharing the topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial, Eli Lilly and Company ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
However the NHS spending watchdog has announced Mounjaro will only be given to 220,000 people in England during the first three years - despite 3.4 million people being eligible for it. Trials have ...
Mounjaro will be made available on the NHS but the rollout will be phased, with only those with the highest need getting the jabs first ...
The NHS spending watchdog has recommended Mounjaro – also known as tirzepatide and made by Eli Lilly – for those with a ...